Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical Relevance of Skin Pain in Atopic Dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cost of Treating Skin Problems in Patients with Diabetes who Use Insulin Pumps and/or Glucose Sensors

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Eric L Simpson
  • Rodney Sinclair
  • Seth Forman
  • Andreas Wollenberg
  • Roland Aschoff
  • Michael Cork
  • Thomas Bieber
  • Jacob P Thyssen
  • Gil Yosipovitch
  • Carsten Flohr
  • Nina Magnolo
  • Catherine Maari
  • Claire Feeney
  • Pinaki Biswas
  • Svitlana Tatulych
  • Hernan Valdez
  • Ricardo Rojo
View graph of relations

BACKGROUND: Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis.

METHODS: In this multicentre, double-blind, randomised phase 3 trial (JADE MONO-1), patients (aged ≥12 years) with moderate-to-severe atopic dermatitis (Investigator Global Assessment score ≥3, Eczema Area and Severity Index [EASI] score ≥16, percentage of body surface area affected ≥10%, and Peak Pruritus Numerical Rating Scale score ≥4) with a bodyweight of 40 kg or more, were enrolled at 69 sites in Australia, Canada, Europe, and the USA. Patients were randomly assigned (2:2:1) to oral abrocitinib 100 mg, abrocitinib 200 mg, or placebo once daily for 12 weeks. Randomisation was done using an interactive response technology system, stratified by baseline disease severity and age. Patients, investigators, and the funder of the study were masked to study treatment. The coprimary endpoints were the proportion of patients who had achieved an Investigator Global Assessment response (score of 0 [clear] or 1 [almost clear] with a ≥2-grade improvement from baseline), and the proportion of patients who achieved at least a 75% improvement in EASI score from baseline (EASI-75) score, both assessed at week 12. Efficacy was assessed in the full analysis set, which included all randomised patients who received at least one dose of study medication. Safety was assessed in all randomised patients. This study is registered with ClinicalTrials.gov, NCT03349060.

FINDINGS: Between Dec 7, 2017, and March 26, 2019, 387 patients were enrolled: 156 were assigned to abrocitinib 100 mg, 154 to abrocitinib 200 mg, and 77 to placebo. All enrolled patients received at least one dose of study treatment and thus were evaluable for 12-week efficacy. Of the patients with available data for the coprimary endpoints at week 12, the proportion of patients who had achieved an Investigator Global Assessment response was significantly higher in the abrocitinib 100 mg group than in the placebo group (37 [24%] of 156 patients vs six [8%] of 76 patients; p=0·0037) and in the abrocitinib 200 mg group compared with the placebo group (67 [44%] of 153 patients vs six [8%] of 76 patients; p<0·0001). Of the patients with available data for the coprimary endpoints at week 12, compared with the placebo group, the proportion of patients who had achieved an EASI-75 response was significantly higher in the abrocitinib 100 mg group (62 [40%] of 156 patients vs nine [12%] of 76 patients; p<0·0001) and abrocitinib 200 mg group (96 [63%] of 153 patients vs nine [12%] of 76 patients; p<0·0001). Adverse events were reported in 108 (69%) of 156 patients in the abrocitinib 100 mg group, 120 (78%) of 154 patients in the abrocitinib 200 mg group, and 44 (57%) of 77 patients in the placebo group. Serious adverse events were reported in five (3%) of 156 patients in the abrocitinib 100 mg group, five (3%) of 154 patients in the abrocitinib 200 mg group, and three (4%) of 77 patients in the placebo group. No treatment-related deaths were reported.

INTERPRETATION: Monotherapy with oral abrocitinib once daily was effective and well tolerated in adolescents and adults with moderate-to-severe atopic dermatitis.

FUNDING: Pfizer.

Original languageEnglish
JournalLancet
Volume396
Issue number10246
Pages (from-to)255-266
Number of pages12
ISSN0140-6736
DOIs
Publication statusPublished - 25 Jul 2020

    Research areas

  • Administration, Oral, Adolescent, Adult, Aged, Australia/epidemiology, Canada/epidemiology, Case-Control Studies, Child, Dermatitis, Atopic/drug therapy, Double-Blind Method, Eczema/drug therapy, Ethnic Groups, Europe/epidemiology, Female, Humans, Janus Kinase 1/antagonists & inhibitors, Male, Middle Aged, Placebos/administration & dosage, Protein Kinase Inhibitors/administration & dosage, Pyrimidines/administration & dosage, Safety, Severity of Illness Index, Sulfonamides/administration & dosage, Treatment Outcome, United States/epidemiology

ID: 60994903